Biotech
Commented by Armin Schulz on October 30th, 2025 | 07:15 CET
BioNxt Solutions: The underrated biotech gem you need to know - Potential partner for Merck and Novo Nordisk
Investing in biotech often feels like a rollercoaster ride. The sector regularly delivers groundbreaking success stories, yet just as often, promising studies come to nothing. For investors, this usually means a nerve-wracking journey with long dry spells and a true all-or-nothing gamble. But what if there was a way to avoid the typical risks without sacrificing the enormous upside potential? The Canadian company BioNxt Solutions is pursuing precisely this approach and could very well change the rules of the game in the biotech industry.
Read
Commented by Nico Popp on October 29th, 2025 | 07:30 CET
AI fantasy at biotech innovators: BioNxt, Roche, Merck & Co.
Biotechnology provides us with the medicines of tomorrow. But even with established active ingredients, innovation is possible. A prime example of this is the Canadian-German company BioNxt Solutions. This article outlines the strategy BioNxt is pursuing, which companies the emerging biotech startup could connect with, what new opportunities AI offers for its business model, and what this could mean for BioNxt shareholders.
Read
Commented by Fabian Lorenz on October 28th, 2025 | 07:15 CET
Better than BioNTech, Evotec & Co.? BioNxt Solutions faces key milestones and is considering an AI takeover – Stock in an upward trend
An exciting alternative to Evotec, BioNTech, and similar companies is BioNxt Solutions. The Canadian-German company's business model is a refreshing departure from traditional biotech companies with their huge research costs. BioNxt reformulates already approved active ingredients. For instance, Ozempic is set to be taken orally instead of by injection in the future. The sublingual cladribine formulation for multiple sclerosis is already well advanced, with its preclinical phase nearing completion. At the same time, CEO Hugh Rogers is considering an acquisition in the field of artificial intelligence to further accelerate development processes. The aforementioned development in the billion-dollar obesity market is also exciting. If a breakthrough succeeds, the Company could soon become a takeover candidate for Big Pharma.
Read
Commented by André Will-Laudien on October 24th, 2025 | 07:35 CEST
BioNxt Solutions advances sublingual MS therapy into decisive development phase
BioNxt Solutions is on the verge of a decisive step in the development of its novel sublingual cladribine formulation for the treatment of multiple sclerosis. Following successful small-animal studies, the Company is now launching a large-scale animal study to optimize dosage ahead of the planned human bioequivalence study in 2026. The orally soluble thin-film technology is designed to enable faster drug absorption, greater bioavailability, and easier administration. At the same time, BioNxt is securing patent protection in key global markets, further strengthening its position in the competitive field of advanced drug delivery systems. With its focus on patient-friendly, precise, and effective therapies, BioNxt could set a new standard in MS treatment. A promising setup for the coming months. What opportunities does the Company offer dynamic investors?
Read
Commented by Carsten Mainitz on October 23rd, 2025 | 07:25 CEST
AI hidden gem NetraMark Holdings is poised for a price surge, TeamViewer crash, and Novo Nordisk supervisory board resigns! What to do?
Artificial intelligence (AI) is widely regarded as a key technology with enormous potential across all industries. The use of AI opens up new opportunities, particularly in the biotechnology and pharmaceutical industries: from faster identification of potential active ingredients to more precise diagnostics and the automation of complex laboratory processes. Companies that make targeted use of AI gain competitive advantages in a highly competitive environment. Following a broad-based bull market, it is worth exploring promising second-tier players.
Read
Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST
Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?
Read
Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST
AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk
Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!
Read
Commented by Nico Popp on October 21st, 2025 | 07:10 CEST
Biotech investors should know these suppliers: Thermo Fisher Scientific, BioNxt, AptarGroup
While new drugs dominate the headlines, it is often suppliers and service providers that deliver solid long-term returns. Three examples: Thermo Fisher Scientific, BioNxt Solutions, and AptarGroup - all key enablers for pharmaceutical and biotech companies. We present their business models and markets, highlighting where investors can spot particular opportunities – especially BioNxt, which occupies exciting niches with its innovations.
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST
Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!
Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.
Read